Department of Interventional Cardiology, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; Department of Interventional Cardiology, Instituto de Cardiologia de Santa Catarina, São José, Brazil; Department of Cardiology, Hospital Universitário Prof Polydoro Ernani de São Thiago, Florianópolis, Brazil.
Department of Interventional Cardiology, Santa Casa de Marília, Marília, Brazil.
JACC Cardiovasc Interv. 2022 May 23;15(10):1009-1018. doi: 10.1016/j.jcin.2022.02.026. Epub 2022 Mar 21.
The aim of this study was to evaluate whether administration of nitroglycerin at the beginning or end of a transradial approach (TRA) procedure would preserve radial patency.
The TRA is becoming the preferred vascular access route in coronary interventions. Radial artery occlusion (RAO) is the most frequent complication. Routine vasodilator treatment aims to reduce spasm and possibly prevent RAO.
The authors designed a prospective, multicenter, randomized, double-blind, 2-by-2 factorial, placebo-controlled trial encompassing patients undergoing the TRA. Patients were randomized to either 500 μg nitroglycerin or placebo; each arm was also subrandomized to early (upon sheath insertion) or late (right before sheath removal) nitroglycerin administration to evaluate the superiority of nitroglycerin in the prevention of RAO with 24 hours on Doppler ultrasound.
A total of 2,040 patients were enrolled. RAO occurred in 49 patients (2.4%). Fifteen of these patients (30.6%) showed re-establishment of flow at 30 days. Nitroglycerin, compared with placebo, did not reduce the risk for RAO at either of the 2 time points (early, 2.5% vs 2.3% [P = 0.66]; late, 2.3% vs 2.5% [P = 0.66]). By multivariable analysis, the presence of spasm (OR: 3.53; 95% CI: 1.87-6.65; P < 0.001) and access achieved with more than 1 puncture attempt (OR: 2.58; 95% CI: 1.43-4.66; P = 0.002) were independent predictors of RAO.
The routine use of nitroglycerin was not associated with a reduction in the rate of RAO, regardless of the time of administration (at the beginning or end of the TRA procedure).
本研究旨在评估经桡动脉途径(TRA)介入治疗时,硝酸甘油起始或结束时给药是否会保持桡动脉通畅。
TRA 已成为冠状动脉介入治疗的首选血管入路。桡动脉闭塞(RAO)是最常见的并发症。常规血管扩张剂治疗旨在减少痉挛并可能预防 RAO。
作者设计了一项前瞻性、多中心、随机、双盲、2×2 析因、安慰剂对照试验,纳入接受 TRA 的患者。患者随机分为硝酸甘油 500μg 或安慰剂组;每个组还被分为早期(鞘管插入时)或晚期(鞘管拔出前)硝酸甘油给药亚组,以评估 24 小时多普勒超声检测预防 RAO 的硝酸甘油优势。
共纳入 2040 例患者。49 例(2.4%)发生 RAO。其中 15 例(30.6%)在 30 天时血流再通。与安慰剂相比,硝酸甘油在两个时间点均不能降低 RAO 风险(早期:2.5%比 2.3%[P=0.66];晚期:2.3%比 2.5%[P=0.66])。多变量分析显示,痉挛的存在(比值比:3.53;95%可信区间:1.87-6.65;P<0.001)和经 1 次以上穿刺尝试获得入路(比值比:2.58;95%可信区间:1.43-4.66;P=0.002)是 RAO 的独立预测因素。
无论给药时间(TRA 操作开始时或结束时)如何,常规使用硝酸甘油均不能降低 RAO 发生率。